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LIPOPROTEIN(A) DETERMINATION
AND RISK OF CARDIOVASCULAR
DISEASE IN SOUTH AFRICAN
PATIENTS WITH FAMILIAL
HYPERCHOLESTEROLAEMIA
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Odendaal, Hans G Kraft, Gerd Utermann, Maritha J Kotze
Objective. A raised plasma level of lipoprotein(a) (Lp(a» is
an established genetic risk factor for coronary heart disease
(om), particularly in patients with concomitant elevation
of low-density lipoprotein (LDL) cholesteroL The current
study focused on the comparison of two commercially
available Lp(a) assay kits to determine whether differences
observed in measured Lp(a) levels could be deemed
negligible in om risk assessment in familial
hypercholesterolaemic (FH) patients.
Design. To compare results obtained on duplicate plasma
samples using two commercially available Lp(a) measuring
kits, the immunoradiometric assay (RIA) and the enzyme-
linked immunoabsorbent assay (ELISA).
Setting. DiVision of Human Genetics, Department of
Obstetrics and Gynaecology, University of Stellenbosch,
Tygerberg, South Africa and the Institute for Medical
Biology and Human Genetics, University of Innsbru~
Austria.
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Subjects. Plasma samples were obtained from 146 family
members of 65 molecularly characterised South African FH
families for comparative analysis.
Results. Using the RIA method, 34 samples (23%) considered
to be in the normal range by the ELISA technique, were
placed in the high-risk group (> 30 mg/ dl). Only one sample,
considered to have a normal Lp(a) level with the RIA
method, was categorised by the ELISA technique as high risk.
Conclusion. O!rr data demonstrate that measuremeAts of Lp(a)
using the RIA method (the only assay available in South
Africa at the time of this study) differ significantly from
those obtained by the reference ELISA technique, suggesting
that misclassification could lead to inaccurate om risk
assessment. This is an important consideration in Afrikaner
FH families, where plasma levels of Lp(a) have been shown
to be elevated significantly in FH patients compared with
non-FH individuals.
s Afr Med J2000; 90: 374-378.
Familial hypercholesterolaemia (FH) contributes significantly
to the high mortality rate from coronary heart disease (CHD)/
especially in the Afrikaner population of South Africa where
the disease prevalence is increased owing to a founder effect.'
FH is an autosomal dominant condition caused by mutations in
the low-density lipoprotein receptor (LDLR) gene, and is
characterised by elevated LDL cholesterol, xanthomas and
premature CHD.l Raised plasma concentrations of
lipoprotein(a) (Lp(a», a subfraction of LDL, are also elevated in
patients with heterozygous FH,'-4 and are generally considered
to be a feature of this disease. Sufficient evidence exists to
suggest that a raised Lp(a) concentration is a strong
independent risk factor for the development of CHD,' and may
therefore confer additional risk of atherosclerosis in FH
patients.
Phenotypic variability observed among FH heterozygotes
with the same LDLR gene defect complicates accurate
identification of individuals with the highest CHD risk....
Variation in the clinical expression of FH observed in a
molecularly characterised South African Afrikaner family
prompted an investigation into the possible allelic effects of
apolipoprotein (apo) E and B polymorphisms, and elevated
Lp(a) levels.' A severely affected 54-year-old proband had
significantly higher Lp(a) levels than his relatively healthy 84-
year-old father with the same LDLR gene mutation, implicating
elevated Lp(a) concentration as a genetic factor contributing to
CHD risk in the family. This family study was subsequently
extended to include 30 FH families with one of the founder-
related Afrikaner mutations D206E (FH 1), V408M (FH 2) or
Dl54N (FH 3), for analysis of Lp(a) levels and possible effects
of the apo(a) locus." A significant effect of LDLR gene mutation
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Table I. Characteristics of familial hypercholesterolaemia (FH)
heterozygotes with and without coronary heart disease (CHD)
.. ,+' indicates the presence of Q-ID.
t '-' indicates the absence of OID.
TC =total cholesterol; TG = triglyceride; HOLC = hi,h-density li~"rotein
cholesterol; IDLC = low-density lipoprotein cholesterol;
FH 1· 3 =Afrikaner founder·related IDLR gene mutations.
measurements obtained in a laboratory in South Africa.
Fifty-four index cases older than 25 years were further
categorised into CHD-positive and CHD-negative FH groups
(Table 1). Patients were recorded as having CHD if they
presented with angina pectoris or had suffered a myocardial
infarction.
Double antibody enzyme-linked immunosorbent
assay (ELISA)
The ELISA assay uses an affinity-purified polyclonal
apolipoprotein (a) antibody for capturing (coating) and the
horseradish peroxidase-conjugated monoclonal antibody IA2
(Boehringer Mannheim, Germany) for detection.' This antibody
does not cross-react with plasminogen.17 Lp(a) concentrations
.were reported in mg/ d!.
32
10:22
45.3 (11.8)
10.18 (1.84)
1.42 (0.67)
1.24 (0.38)
8.29 (1.74)
25 (78.1%)
4 (12.5%)
3 (9.4%)
CHD+*
'22
10:12
50.3 (13.4)
10.27 (2.54)
1.67 (0.73)
1.25 (0.36)
8.25 (2.55)
10 (45.5%)
7 (31.8%)
5 (22.7%)
Number of patients
Male/female ratio
Mean age (yrs)
Mean TC (mmol/I)
Mean TG (mmol/l)
Mean HOLC (mmol/I)
Mean LDLC (mmol/1)
FH 1 mutation (N)
FH 2 mutation (N)
FH 3 mutation (N)
Apo(a) solid phase two-site immunoradiometric
assay (RIA)
Antibodies, standards and reagents were obtained as test kit
components from Pharmacia Diagnostics AB (Uppsala,
Sweden). The RIA assay was performed according to the
manufacturer's instructions and calibrated using the provided
standards. The method uses two monoclonal antibodies
directed against separate antigenic determinants on the apo(a)
molecule. During incubation, apo(a) in the sample reacts with
E'l-anti-apo(a) antibodies and anti-apo(a) antibodies bound to
Sepharose-particles. The antigen/ antibody sandwich is
separated from excess tracer by centrifugation and decantation,
and the radioactivity in the pellet is counted. Results were
reported in mg / dl; according to the manufacturer 1 U / I would
correspond with 0.1 mg/ d!.
MATERIALS AND METHODS
Subjects
Blood samples were obtained with informed consent from 146
members of 65 FH families. The proband in each family has
been characterised at the molecular level with one of the
Afrikaner founder-related LDLR gene mutations, D206E (FH1),
V408M (FH 2) or Dl54N (FH 3): Whole blood was kept on ice
and centrifuged within 4 hours to recover the plasma.
Duplicate samples were stored at -70°C, while a single aliquot
of each sample was sent on dry ice by air to Innsbruck for
determination of Lp(a) levels and for comparison with
on Lp(a) concentration could be demonstrated, independent of
allelic effects at the apo(a) locus. Given the interactive effect of
high Lp(a) and elevated LDL on CHD risk, we deduced from
this study that elevated Lp(a) may contribute to the CHD risk
in (South African) FH patients.
The function and metabolism of Lp(a) is unknown, but it has
been suggested that Lp(a) may aid in wound healing by
binding fibrin at wound sites. lO Subsequent to this Hoffmann et
al.1I have demonstrated that Lp(a) competes with LDL for LDL
receptors, while Snyder ~t al. E showed that only 25% of Lp(a) is
catabolised via the LDL pathway. Various contradictory reports
have since been published on the significance of Lp(a) as a risk
factor for CHD.' Two independent studies
'
3.14 indicated that for
Lp(a) to exert its atherogenic effect, an elevation in LDL levels
is essential, suggesting biochemical interaction between LDL
and Lp(a). Various studies have supported this,' but the
mechanism(s) of interaction still remains to be established.
The many contradictory reports in the literature with regard
to Lp(a) are confusing and may lead to an underestimation of
its significance as a risk factor for CHD. Berg15 provided
numerous reasons for different outcomes of studies on disease
association, including technical problems encountered in
measurement of Lp(a) concentration. It has been shown!· that
the design as well as the antibodies utilised for Lp(a)
determination are factors that can greatly influence the
outcome of an assay.
The current study focused on the comparison of two
commercially available Lp(a) assay kits to determine whether
differences observed in measured Lp(a) levels could be deemed
negligible in CHD risk assessment in FH patients. The
immunoradiometric assay (RIA) - the only Lp(a) assay
available in South Africa at the time this study was initiated -
is based on a direct sandwiching technique in which two
monoclonal antibodies are directed against separate antigenic
determinants on the apolipoprotein molecule. The second
method is based on a double antibody enzyme-linked
immunosorbent assay (ELISA), using an affinity-purified
polyclonal apo(a) antibody for coating and horseradish
peroxidase-conjugated antibody for detection.
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DISCUSSION
Fig. 1. Bland-Altman's plot ofagreement. Data have been plotted to
show the difference between the two methods (EU5A-RIA) against
the average measurement.
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CHD, despite the fact that the receptor-negative Fill mutation
was more prevalent (31.8% v. 12.5%) in the former group (Table
I). Previous studies··19 have shown that the FH 2 mutation was
associated with significantly higher cholesterol levels than the
receptor-defective FH 1 or FH 3 mutations.
This comparative study was prompted by an earlier suggestion
by Berg15 that contradictory results obtained in the analysis of
Lp(a) as a risk factor for CHD may be a consequence of
technical problems rather than lack of association. The main
objective of the study was to determine whether the RlA
method, used routinely in South Africa at the time of the study,
would provide similar results to the internationally accepted
double-antibody ELISA technique. We collected duplicate
plasma samples of 146 family members from 65 Afrikaner FH
RESULTS
Statistical analysis
A mixed-model analysis of variance (ANOVA) was applied to
log transformed Lp(a) levels. Independent variables, namely
age, gender and familial dependence, were considered in the
analysis. To determine whether agreement existed between the
two techniques, a Bland-Altman method!' was used for
comparison. McNemar's chi-square test was used to determine
whether the difference observed was statistically significant.
Plasma Lp(a) levels were determined in 146 individuals from
65 FH families using both an internationally accepted ELlSA
technique and an RlA method, widely used at the time the
study was initiated in South Africa, to establish whether values
observed with the two methods were compatible. Table IT
demonstrates results of the 146 samples classified according to
Lp(a) levels measured using the two different techniques. The
RlA method placed 34 samples in the high-risk group (> 30
mg/ dl), whereas using the ELISA technique these were
considered to be within the normal range. The ELISA technique
indicated only a single sample in the high-risk group, which
was considered normal by the RlA method. A statistically
significant difference was detected between the two methods (P
< 0.0001) using the McNemar chi-squared test.
Analysis of the data showed a negatively skewed
distribution with a mean of -22.2 mg / dl (standard deviation
(SD) = 30.93) (Fig. 1). The negative mean indicates that the RlA
method preferentially overestimates Lp(a) levels, and would
thereby include more false-positives compared with the ELISA
technique. Using a paired t-test, a statistically significant
difference was observed between the two methods (P < 0.0001).
To determine whether Lp(a) levels differ in FH patients with
and without CHD, we analysed 54 index cases older than 25
years using the least squares method. No significant association
with CHD was observed with either the ELISA or the RlA
method (P = 0.55 and 0.49, respectively) after adjusting for age
and gender (Table ill). Plasma cholesterol concentration did not
differ significantly between FH patients with and without
Table n. Classification of 146 samples according to Lp(a) concentrations obtained with the immunoradiometric assay (RIA) and the enzyme-
linked immunosorbent~y (ELISA)
RIA
<30 mg/dl (N = 59)
(normal range)
>30 mg/dl (N = 87)
(high risk)
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ELlSA
ELISA
< 30 mg/dl (N = 92)
(normal range)
> 30 mg/ dl (N = 54)
(high risk)
58
1
34
53
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Table m. Comparison of two methods in determining risk for coronaty heart disease (CHD) in familial hypercholesterolaemia (FH)
heterozygotes using the least square means
Least square mean Standard error Range
CHD+ CHD- CHD+ CHD- CHD+ CHD-
Method (N =22) (N =32) (N =22) {N = 32) (N=22) (N=32) P-value
ELISA 2.3348 22546 0.0997 0.087 25350 - 2.1347 2.4293 - 2.0799 0.55
RIA 2.6561 2.5674 0.0951 0.083 2.8471 - 2.4651 2.7341 - 2.4007 0.49
Values represent log transformation of Lp(a) concentrations (mg/dl).
families for Lp(a) analyses, initially for a sib-pair approach
based on genotype information for both the LDLR and apo(a)
genes: and subsequently to determine whether differences
observed in measurements using the ELlSA and RlA methods
could be considered negligible in patient management. This
proved to be an important consideration in Afrikaner FH
families, since the previous study' of 30 informative FH
families demonstrated significantly elevated Lp(a) levels in FH
individuals compared with non-FH relatives. This finding
provided evidence for the presence of additional CHD risk in
FH individuals, making accurate Lp(a) determination essential
in South African patients.
Statistical comparison of the ELISA and RlA methods utilised
in this study indicated that the degree of variation ·observed
would be totally unacceptable for clinical purposes. For
accurate identification of individuals likely to develop CHD, it
should be borne in mind that the RlA method is likely to
include many more false-positives than the ELISA technique.
The same observation was made by Marz et al. 16 when
comparing the RlA method with two other commercially
available assays for Lp(a) determination. In this respect it is
important to take into account the fact that, to date, no Lp(a)-
lowering drugs are available, although various studies have
proposed that lowering LDL in individuals with high plasma
Lp(a) levels may reduce CHD progression.s
Since FH may be associated with an increase in plasma
Lp(a), elevated levels could be regarded as characteristic of this
disease. Plasma Lp(a) levels in 22 of the Afrikaner FH index
patients who suffer from CHD were, however, not significantly
different from 32 FH cases without CHD using either the
ELISA or the RlA method, after adjusting for age and gender.
At a molecular level the allelic distribution at the apo(a) locus'
was similar in the two FH groups (P > 0.5) (data not shown).
In an attempt to increase our sample size, we included an
additional 11 FH family members above the age of 25 years (N
= 65), but still no association could be demonstrated between
Lp(a) concentration and CHD (data not shown). These results
may reflect the small sample size, the composition of the FH
patient cohort (e.g. younger individuals may still develop
CHD) and/ or the difficulty in demonstrating the effect of a
minor gene in the presence of a major gene such as the LDLR
gene, known to be responsible for the disease in our study
population. It has been suggested20.2! that failure to demonstrate
an association between raised Lp(a) levels and CHD in FH
patients may be a consequence of either asymptomatic
coronary disease that is common in FH, or a high mortality rate
in affected individuals owing to gene-gene interaction.
Comparative studies of CHD risk among FH patients can
therefore be misleading and prospective studies are needed to
address properly the issue of the degree of CHD risk imposed
by raised Lp(a) levels in this group of patients.
In summary, our results have demonstrated that the RlA
method for determination of Lp(a) concentration differs
significantly from the reference ELISA technique. This may
hinder the identification of individuals with a high risk of
CHD in the South African population. Consequently, the
continued use of the RlA method for measurement of Lp(a)
should be reconsidered in order to facilitate a more effective
patient management regimen. Candidates for Lp(a)
measurement should include patients with early coronary
disease in the absence of conventional risk factors and those
with a family history of premature CHD. Reduction of
modifiable risk factors in families with elevated Lp(a) should
be a priority until an acceptable means of reducing Lp(a) levels
is found.
This study was supported by the University of Stellenbosch, the
South African Medical Research Council and Grant PL 951678 from
the Federal Ministry of Science and Transport
(Zusatzfinanzierung/EU-Project) to G Utermann. The authors wish
to thank E Langenhoven and L Theart for LDLR gene mutation
screening and Drs E Terblanche, A V Peeters and E Dollinger for
helpful discussion.
References
1. Goldstein /L. Hobbs HH. Brown MS. Familial hypercholesterolemia. In: Scrlver CR. Beaudet
AL, Sly WS, Valle 0, eds. The Metabolic Basis of Inherited Disease. New York.: McCraw-Hill,
1995: 1981-2030.
2. Seftel He, Baker se, Sa...'l.dler MP. et al. A host of hypercholesterolaemic homozygotes in
South Africa. BMI 1980; 281: 633-<i36.
3. Utermann G, Hopplicher F, Dieplinger H, Seed M, Thompson C, Boerwinkle E. Defects in the
low density lipoprotein receptor gene affect lipoprotein(a) levels: Multiplicative interaction of
two gene loci associated with premature atherosclerosis. Proc N!ltl Acad Sci USA 1989; 86:
4171-4174.
4. Wtklund 0, Angelin B, Olo£5on S, et al. Apolipoprotein{a) and ischaemic heart disease in
familial hypercholesterolaemia.l.Jmcet 1990; 2: 1360-1363.
5. Maher VMG, Brown BC. Upoprotein{a) and coronary heart disease. Cun Opin LipidoI 1995; 6:
~235.
6. Kotze MJ, De VLlliers WJS, Steyn K. et al. Phenotypic variation among familial
hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor
mutations. ArtmoscJer Thromb 1993; 13: 146(}.1468.
7. Kotze MJ, Davis Hj, Bissbort 5, Langenhoven E; Brusnicky J, Oosthuizen Cn.lntrafamiliaJ
variability in the clinical expression of familial hypercholesterolemia: importance of risk
factor determination for genetic counselling. Clin Genet 1993; 43: 295-299.
8. Pimstone SN, Sun X-M, Du Souich C. Frohlich n, Hayden MR, Soutar AI<. Phenotypic
variation in heterozygous familial hypercholesterolaemia Arlmoscler Thromb Vase Bioi 1998;
18,309-315.
9. .1Jngenhel A, Krait HG, Kotze MJ, et aI, 'Concentration of the atherogenic Lp(a) are elevated in
FH. Eu, I Hum Genet 1998; 6, 50-56.
10. Brown MS, Goldstein Jl. Plasma lipoproteins: teaching old dogmas new tricks. Nature 1987;
330,113-114.
11. Hoffmann SL, Eaton DL, Brown MS, McConathy \\1, Goldstein JL, Hammer RE.
Overexpression of low density lipoprotein receptors leads to accelerated catabolism of Lp(a)
in transgenic mice. JClin Invest 1990; 85: 1542-1547.
12 Snyder MI... Polacek 0, Scanu A.~ Fless GM. Comparative binding and degradation of
lipoprotein(a) and low density lipoprotein by human monocyte-derived macrophages. JBioi
Chem 1992; 267, 339-346.
13. Armstrong VW, Cremer P. Eberle E, et al. The association between serum Lp(a} concentration
and angiographically assessed coronary atherosclerosis. Dependence on serum LqL levels.
Atherosclerosis 1986; 62: 249-257.
14. La\'ln RM. Wade Of, Hammer RE, Otiesa G, Verstudy JG, Rubin EM. Atherogenesis in
transgenic mice expressing human apolipoprotein{a). Nature 1992; 360: 670-6n.
15. Berg K. Confounding results of Lp{a} lipoprotein measurements with some test kits. Clin
Gene' 1994; 46, 57-62.
16. Man W, Siekmeier R..M. Gross W, Kostner GM Determination of lipoprotein(a): Evaluation of
three methods. Eur JClin Chem Clin Biochem 1993; 31: 295-301.
17. Menze1 HJ, Dieplinger H, Lackner C, et al. Abetaljpoproteinemia with an ApoB-l00-
lipoprotein(a} glycoprotein complex in plasma- indication for an assembly defect.. J BioI Chem
1990; 265, 981-966.
18. Bland JM, Altman DC. Statistical methods for assessing agreement behveen two methods of
dinical measurement. umat 1986; 1: 307-310.
19. Graadt van RoggenJF, van der Westhuyzen OR, Coetzee CA, et al. FH Afrikaner-3 LDL
receptor mutation results in defective LDL receptors and causes a mild form of familial
hypercholesterolemia Arterioscler Thromb Vase Bioi 1995; 15: 765-~.
20. Mbewu AD, Bhalnagar D, Durrington PN, Hunt L, Ishola M, Anol S. Serum lipoprotein(a) in
patients heterozygous for familial hypercholesterolemia,. their relatives and unrelated control
population. Arterioscler Thromb 1991; 11: 290-297.
21. Bowden J-F, Pritchard PH, Frohlich n. Lp(a) concentration and apo(a} isoform size. Relation
to the presence of coronary disease in familial hypercholesterolemia. Arterioscler Thromb 1994;
140 1561-1568.
Accepted 27 Sep 1999.
April 2000, Vol. 90, .No_ 4 SAMJ
To WHAT EXTENT DOES SOUTH
AFRICAN MENTAL HEALTH AND
SUBSTANCE ABUSE RESEARCH
ADDRESS PRIORITY ISSUES?
Alan J Flisher, Charles D H Parry, Dan J Stein
Objective. To investigate the extent to which South African
mental health research addresses priority issues.
Design. Cross-sectional survey of conference presentations_
Setting. The most recent conferences of the following
professional societies: the Epidemiological Society of
Southern Africa, the Psychological Society of South Africa,
the Society of Psychiatrists of South Africa, and the South
African Association for Child and Adolescent Psychiatry
and Allied Disciplines.
Main outcome measures. Whether the presentations
addressed priority areas as defined in the list 'Selected
priority areas of research' compiled by the Mental Health
and Substance Abuse Thrust of the Medical Research
Council, and if so which priority areas were addressed_
ResuIts_ There were 627 presentations, with 267 (43%) on
mental health or substance abuse. Seventy-eight papers
(29%) reported original research in a priority area
identified by the Medical Research Council. Of these, 73
(94%) were on mental health and 5 (6%) were on substance
abuse. Of the 73 papers on mental health, 33 (45%)
addressed topics in health problem research, 7 (10%)
aetiology research, 22 (30%) intervention research, and 11
(15%) operational and health systems research.
Conclusion. Much South African mental health research does
not address priority issues. There is a particular dearth of
research addressing substance abuse research priorities.
Funding mechanisms and research capacity development
initiatives could help to rectify the situation.
s Afr Med J 2000; 90: 378-380.
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